{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:52:08Z","timestamp":1778788328450,"version":"3.51.4"},"publisher-location":"New York, NY","reference-count":49,"publisher":"Springer US","isbn-type":[{"value":"9781071607701","type":"print"},{"value":"9781071607718","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-1-0716-0771-8_7","type":"book-chapter","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:02:49Z","timestamp":1598857369000},"page":"99-109","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Degradation of Toxic RNA in Myotonic Dystrophy Using Gapmer Antisense Oligonucleotides"],"prefix":"10.1007","author":[{"given":"Quynh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"3","key":"7_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ncl.2014.04.011","volume":"32","author":"CA Thornton","year":"2014","unstructured":"Thornton CA (2014) Myotonic dystrophy. Neurol Clin 32(3):705\u2013719. \nhttps:\/\/doi.org\/10.1016\/j.ncl.2014.04.011","journal-title":"Neurol Clin"},{"issue":"5","key":"7_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1034\/j.1399-0004.2001.590508.x","volume":"59","author":"G Siciliano","year":"2001","unstructured":"Siciliano G, Manca M, Gennarelli M et al (2001) Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clin Genet 59(5):344\u2013349","journal-title":"Clin Genet"},{"issue":"4","key":"7_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000016209","volume":"2","author":"A Magee","year":"1999","unstructured":"Magee A, Nevin NC (1999) The epidemiology of myotonic dystrophy in Northern Ireland. Community Genet 2(4):179\u2013183. \nhttps:\/\/doi.org\/10.1159\/000016209","journal-title":"Community Genet"},{"issue":"2-3","key":"7_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00439-005-1298-8","volume":"117","author":"V Yotova","year":"2005","unstructured":"Yotova V, Labuda D, Zietkiewicz E et al (2005) Anatomy of a founder effect: myotonic dystrophy in Northeastern Quebec. Hum Genet 117(2-3):177\u2013187. \nhttps:\/\/doi.org\/10.1007\/s00439-005-1298-8","journal-title":"Hum Genet"},{"issue":"7","key":"7_CR5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ejhg.2011.23","volume":"19","author":"T Suominen","year":"2011","unstructured":"Suominen T, Bachinski LL, Auvinen S et al (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19(7):776\u2013782. \nhttps:\/\/doi.org\/10.1038\/ejhg.2011.23","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"7_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1086\/378566","volume":"73","author":"LL Bachinski","year":"2003","unstructured":"Bachinski LL, Udd B, Meola G et al (2003) Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy\/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 73(4):835\u2013848. \nhttps:\/\/doi.org\/10.1086\/378566","journal-title":"Am J Hum Genet"},{"issue":"4","key":"7_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/0092-8674(92)90154-5","volume":"68","author":"JD Brook","year":"1992","unstructured":"Brook JD, McCurrach ME, Harley HG et al (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3\u2032 end of a transcript encoding a protein kinase family member. Cell 68(4):799\u2013808","journal-title":"Cell"},{"issue":"15","key":"7_CR8","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1001\/jama.1993.03500150072029","volume":"269","author":"JB Redman","year":"1993","unstructured":"Redman JB, Fenwick RG Jr, Fu YH et al (1993) Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. JAMA 269(15):1960\u20131965","journal-title":"JAMA"},{"issue":"2","key":"7_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/422762","volume":"75","author":"N De Temmerman","year":"2004","unstructured":"De Temmerman N, Sermon K, Seneca S et al (2004) Intergenerational instability of the expanded CTG repeat in the DMPK gene: studies in human gametes and preimplantation embryos. Am J Hum Genet 75(2):325\u2013329. \nhttps:\/\/doi.org\/10.1086\/422762","journal-title":"Am J Hum Genet"},{"issue":"12","key":"7_CR10","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1212\/WNL.43.12.2674","volume":"43","author":"T Ashizawa","year":"1993","unstructured":"Ashizawa T, Dubel JR, Harati Y (1993) Somatic instability of CTG repeat in myotonic dystrophy. Neurology 43(12):2674\u20132678","journal-title":"Neurology"},{"issue":"1","key":"7_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.410350116","volume":"35","author":"CA Thornton","year":"1994","unstructured":"Thornton CA, Johnson K, Moxley RT 3rd (1994) Myotonic dystrophy patients have larger CTG expansions in skeletal muscle than in leukocytes. Ann Neurol 35(1):104\u2013107. \nhttps:\/\/doi.org\/10.1002\/ana.410350116","journal-title":"Ann Neurol"},{"issue":"5531","key":"7_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1062125","volume":"293","author":"CL Liquori","year":"2001","unstructured":"Liquori CL, Ricker K, Moseley ML et al (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293(5531):864\u2013867. \nhttps:\/\/doi.org\/10.1126\/science.1062125","journal-title":"Science"},{"issue":"6","key":"7_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1212\/01.wnl.0000333665.01888.33","volume":"72","author":"LL Bachinski","year":"2009","unstructured":"Bachinski LL, Czernuszewicz T, Ramagli LS et al (2009) Premutation allele pool in myotonic dystrophy type 2. Neurology 72(6):490\u2013497. \nhttps:\/\/doi.org\/10.1212\/01.wnl.0000333665.01888.33","journal-title":"Neurology"},{"issue":"4","key":"7_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1212\/01.WNL.0000054481.84978.F9","volume":"60","author":"JW Day","year":"2003","unstructured":"Day JW, Ricker K, Jacobsen JF et al (2003) Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60(4):657\u2013664","journal-title":"Neurology"},{"issue":"3","key":"7_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1212\/WNL.55.3.383","volume":"55","author":"C Schneider","year":"2000","unstructured":"Schneider C, Ziegler A, Ricker K et al (2000) Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurology 55(3):383\u2013388","journal-title":"Neurology"},{"issue":"4","key":"7_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbadis.2014.05.019","volume":"1852","author":"G Meola","year":"2015","unstructured":"Meola G, Cardani R (2015) Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 1852(4):594\u2013606. \nhttps:\/\/doi.org\/10.1016\/j.bbadis.2014.05.019","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"7_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","volume":"27","author":"C Turner","year":"2014","unstructured":"Turner C, Hilton-Jones D (2014) Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 27(5):599\u2013606. \nhttps:\/\/doi.org\/10.1097\/WCO.0000000000000128","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"7_CR18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","volume":"11","author":"B Udd","year":"2012","unstructured":"Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11(10):891\u2013905. \nhttps:\/\/doi.org\/10.1016\/S1474-4422(12)70204-1","journal-title":"Lancet Neurol"},{"issue":"2","key":"7_CR19","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1093\/hmg\/ddl181","volume":"15","author":"RJ Osborne","year":"2006","unstructured":"Osborne RJ, Thornton CA (2006) RNA-dominant diseases. Hum Mol Genet 15(2):R162\u2013R169. \nhttps:\/\/doi.org\/10.1093\/hmg\/ddl181","journal-title":"Hum Mol Genet"},{"issue":"15","key":"7_CR20","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1038\/sj.emboj.7600300","volume":"23","author":"TH Ho","year":"2004","unstructured":"Ho TH, Charlet BN, Poulos MG et al (2004) Muscleblind proteins regulate alternative splicing. EMBO J 23(15):3103\u20133112. \nhttps:\/\/doi.org\/10.1038\/sj.emboj.7600300","journal-title":"EMBO J"},{"issue":"Pt 6","key":"7_CR21","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1042\/BST0371281","volume":"37","author":"JE Lee","year":"2009","unstructured":"Lee JE, Cooper TA (2009) Pathogenic mechanisms of myotonic dystrophy. Biochem Soc Trans 37(Pt 6):1281\u20131286. \nhttps:\/\/doi.org\/10.1042\/BST0371281","journal-title":"Biochem Soc Trans"},{"issue":"17","key":"7_CR22","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1093\/emboj\/19.17.4439","volume":"19","author":"JW Miller","year":"2000","unstructured":"Miller JW, Urbinati CR, Teng-Umnuay P et al (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19(17):4439\u20134448. \nhttps:\/\/doi.org\/10.1093\/emboj\/19.17.4439","journal-title":"EMBO J"},{"issue":"33","key":"7_CR23","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","volume":"106","author":"SA Mulders","year":"2009","unstructured":"Mulders SA, van den Broek WJ, Wheeler TM et al (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A 106(33):13915\u201313920. \nhttps:\/\/doi.org\/10.1073\/pnas.0905780106","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"7_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.cell.2012.06.041","volume":"150","author":"ET Wang","year":"2012","unstructured":"Wang ET, Cody NA, Jog S et al (2012) Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins. Cell 150(4):710\u2013724. \nhttps:\/\/doi.org\/10.1016\/j.cell.2012.06.041","journal-title":"Cell"},{"issue":"1","key":"7_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","volume":"28","author":"NM Kuyumcu-Martinez","year":"2007","unstructured":"Kuyumcu-Martinez NM, Wang GS, Cooper TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28(1):68\u201378. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2007.07.027","journal-title":"Mol Cell"},{"issue":"1","key":"7_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1097-2765(02)00563-4","volume":"10","author":"A Mankodi","year":"2002","unstructured":"Mankodi A, Takahashi MP, Jiang H et al (2002) Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 10(1):35\u201344","journal-title":"Mol Cell"},{"issue":"1","key":"7_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1085\/jgp.200609635","volume":"129","author":"JD Lueck","year":"2007","unstructured":"Lueck JD, Mankodi A, Swanson MS et al (2007) Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 129(1):79\u201394. \nhttps:\/\/doi.org\/10.1085\/jgp.200609635","journal-title":"J Gen Physiol"},{"issue":"1","key":"7_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ng704","volume":"29","author":"RS Savkur","year":"2001","unstructured":"Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 29(1):40\u201347. \nhttps:\/\/doi.org\/10.1038\/ng704","journal-title":"Nat Genet"},{"issue":"1","key":"7_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1073\/pnas.1013343108","volume":"108","author":"T Zu","year":"2011","unstructured":"Zu T, Gibbens B, Doty NS et al (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A 108(1):260\u2013265. \nhttps:\/\/doi.org\/10.1073\/pnas.1013343108","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"35","key":"7_CR30","doi-asserted-by":"publisher","first-page":"20246","DOI":"10.1074\/jbc.270.35.20246","volume":"270","author":"M Maeda","year":"1995","unstructured":"Maeda M, Taft CS, Bush EW et al (1995) Identification, tissue-specific expression, and subcellular localization of the 80- and 71-kDa forms of myotonic dystrophy kinase protein. J Biol Chem 270(35):20246\u201320249","journal-title":"J Biol Chem"},{"key":"7_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7:E13. \nhttps:\/\/doi.org\/10.3390\/jpm7040013","journal-title":"J Pers Med"},{"issue":"3","key":"7_CR32","first-page":"1202","volume":"11","author":"Q Nguyen","year":"2019","unstructured":"Nguyen Q, Yokota T (2019) Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy. Am J Transl Res 11(3):1202\u20131218","journal-title":"Am J Transl Res"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/jpm3030144","volume":"3","author":"J Lee","year":"2013","unstructured":"Lee J, Yokota T (2013) Antisense therapy in neurology. J Pers Med 3:144\u2013176. \nhttps:\/\/doi.org\/10.3390\/jpm3030144","journal-title":"J Pers Med"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44:6518\u20136548. \nhttps:\/\/doi.org\/10.1093\/nar\/gkw236","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"7_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1089\/nat.2014.0506","volume":"24","author":"F Eckstein","year":"2014","unstructured":"Eckstein F (2014) Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24(6):374\u2013387. \nhttps:\/\/doi.org\/10.1089\/nat.2014.0506","journal-title":"Nucleic Acid Ther"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.addr.2015.04.005","volume":"87","author":"RL Juliano","year":"2015","unstructured":"Juliano RL, Carver K (2015) Cellular uptake and intracellular trafficking of oligonucleotides. Adv Drug Deliv Rev 87:35\u201345. \nhttps:\/\/doi.org\/10.1016\/j.addr.2015.04.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"7_CR37","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1039\/c1cs15048k","volume":"40","author":"MA Campbell","year":"2011","unstructured":"Campbell MA, Wengel J (2011) Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 40(12):5680\u20135689. \nhttps:\/\/doi.org\/10.1039\/c1cs15048k","journal-title":"Chem Soc Rev"},{"issue":"14","key":"7_CR38","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1021\/ja710342q","volume":"130","author":"SM Rahman","year":"2008","unstructured":"Rahman SM, Seki S, Obika S et al (2008) Design, synthesis, and properties of 2\u2032,4\u2032-BNA(NC): a bridged nucleic acid analogue. J Am Chem Soc 130(14):4886\u20134896. \nhttps:\/\/doi.org\/10.1021\/ja710342q","journal-title":"J Am Chem Soc"},{"issue":"12","key":"7_CR39","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/mt.2011.191","volume":"19","author":"M Nakamori","year":"2011","unstructured":"Nakamori M, Gourdon G, Thornton CA (2011) Stabilization of expanded (CTG)\u2217(CAG) repeats by antisense oligonucleotides. Mol Ther 19(12):2222\u20132227. \nhttps:\/\/doi.org\/10.1038\/mt.2011.191","journal-title":"Mol Ther"},{"issue":"11","key":"7_CR40","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.1073\/pnas.1117019109","volume":"109","author":"JE Lee","year":"2012","unstructured":"Lee JE, Bennett CF, Cooper TA (2012) RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci U S A 109(11):4221\u20134226. \nhttps:\/\/doi.org\/10.1073\/pnas.1117019109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7409","key":"7_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler TM, Leger AJ, Pandey SK et al (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111\u2013115. \nhttps:\/\/doi.org\/10.1038\/nature11362","journal-title":"Nature"},{"issue":"1","key":"7_CR42","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1038\/s41467-018-07517-y","volume":"9","author":"N Hu","year":"2018","unstructured":"Hu N, Antoury L, Baran TM et al (2018) Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1. Nat Commun 9(1):5227. \nhttps:\/\/doi.org\/10.1038\/s41467-018-07517-y","journal-title":"Nat Commun"},{"key":"7_CR43","unstructured":"Ionis Pharmaceuticals (2017) Ionis Pharmaceuticals Reports on DMPKRx Phase 1\/2 Clinical Trial. \nhttps:\/\/us8.campaign-archive.com\/?u=8f5969cac3271759ce78c8354&id=8cc67ae9b8&e=cd1f4d18fe\n\n. Accessed 30 September 2019"},{"key":"7_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.9","volume":"2","author":"A Gonzalez-Barriga","year":"2013","unstructured":"Gonzalez-Barriga A, Mulders SA, van de Giessen J et al (2013) Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy. Mol Ther Nucleic Acids 2:e81. \nhttps:\/\/doi.org\/10.1038\/mtna.2013.9","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"7_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1021\/jm801294h","volume":"52","author":"PP Seth","year":"2009","unstructured":"Seth PP, Siwkowski A, Allerson CR et al (2009) Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52(1):10\u201313. \nhttps:\/\/doi.org\/10.1021\/jm801294h","journal-title":"J Med Chem"},{"issue":"3","key":"7_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1089\/nat.2013.0422","volume":"23","author":"SA Burel","year":"2013","unstructured":"Burel SA, Han SR, Lee HS et al (2013) Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther 23(3):213\u2013227. \nhttps:\/\/doi.org\/10.1089\/nat.2013.0422","journal-title":"Nucleic Acid Ther"},{"issue":"2","key":"7_CR47","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/jpet.115.226969","volume":"355","author":"SK Pandey","year":"2015","unstructured":"Pandey SK, Wheeler TM, Justice SL et al (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J Pharmacol Exp Ther 355(2):329\u2013340. \nhttps:\/\/doi.org\/10.1124\/jpet.115.226969","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"7_CR48","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1021\/acschembio.7b00416","volume":"12","author":"KS Manning","year":"2017","unstructured":"Manning KS, Rao AN, Castro M et al (2017) BNA(NC) Gapmers revert splicing and reduce RNA foci with low toxicity in Myotonic dystrophy cells. ACS Chem Biol 12(10):2503\u20132509. \nhttps:\/\/doi.org\/10.1021\/acschembio.7b00416","journal-title":"ACS Chem Biol"},{"issue":"16","key":"7_CR49","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218. \nhttps:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-0771-8_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T07:04:12Z","timestamp":1598857452000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-0716-0771-8_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9781071607701","9781071607718"],"references-count":49,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-0771-8_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"1 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}